Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Harvard Business School
Merck
Johnson and Johnson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR FLORBETAPIR F-18


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Florbetapir F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00702143 ↗ A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed Avid Radiopharmaceuticals Phase 2 2008-06-01 Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
NCT00857415 ↗ Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain Completed Avid Radiopharmaceuticals Phase 3 2008-12-01 The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
NCT00857506 ↗ Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45) Completed Avid Radiopharmaceuticals Phase 2 2009-01-01 The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease. Hypothesis 1: The probability a subject will experience progressive cognitive impairment within 36 months of imaging will be greater in subjects whose 18F-AV-45 PET scan was rated amyloid positive compared to subjects whose PET scan was rated amyloid negative. The secondary objective is to determine the stability, over 36 months of a clinical diagnosis, of AD in patients with an amyloid positive 18F-AV-45 PET. Hypothesis 2: The diagnosis of AD will remain unchanged in patients whose PET scan were rated as amyloid positive.
NCT00857532 ↗ Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 ↗ Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed National Institutes of Health (NIH) Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT00857532 ↗ Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients Completed Avid Radiopharmaceuticals Phase 2 2009-01-01 The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
NCT01383161 ↗ 18-Month Study of Memory Effects of Curcumin Completed University of California, Los Angeles Phase 2 2012-03-01 This project is designed to study the effects of the dietary supplement curcumin on age-related cognitive impairment. In particular, the study seeks to determine the effects of curcumin on cognitive decline and the amount of abnormal amyloid protein in the brain. Genetic risk will also be studied as a potential predictor of cognitive decline. Subjects will be randomly assigned to one of two treatment groups: either a placebo twice daily or the curcumin supplement (Theracurmin┬«, containing 90 mg of curcumin). The investigators expect that the volunteers receiving the curcumin supplement will show less evidence of decline after 18 months than those receiving the placebo. The investigators predict that cognitive decline and treatment response will vary according to genetic risk for Alzheimer's. The investigators will study subjects with memory complaints aged 50-90 years. Initially, subjects will undergo a clinical assessment, an MRI and a blood draw to determine genetic risk and to rule out other neurodegenerative disorders linked to memory complaints. Subsequently, subjects will undergo an -(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) PET scan and a baseline neuropsychological assessment to confirm a diagnosis of MCI or normal aging. Once enrolled, subjects will begin taking the supplement (either curcumin or a placebo). Some of the initial subjects will be asked to return every three months for regular MRIs. Every 6 months, subjects will also receive neuropsychological assessments. At the conclusion of the study, subjects will be asked to complete a final neuropsychological assessment, MRI scan, PET scan and blood draw. Additional blood will be drawn at baseline and at 18 months and frozen to assess inflammatory markers if cognitive outcomes are positive. FDDNP-PET scans will be used to measure the amount of abnormal amyloid plaque- and tau tangle-proteins in the brain; the MRIs will be used to monitor supplement side effects and measure brain structure; the neuropsychological assessments will monitor rates of cognitive decline; the blood draws will be used to determine genetic risk and to test levels of inflammatory markers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Florbetapir F-18

Condition Name

Condition Name for Florbetapir F-18
Intervention Trials
Alzheimer's Disease 19
Alzheimer Disease 11
Mild Cognitive Impairment 7
Cardiac Amyloidosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Florbetapir F-18
Intervention Trials
Alzheimer Disease 32
Cognitive Dysfunction 13
Cognition Disorders 9
Mild Cognitive Impairment 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Florbetapir F-18

Trials by Country

Trials by Country for Florbetapir F-18
Location Trials
United States 137
Australia 7
Canada 6
Italy 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Florbetapir F-18
Location Trials
California 12
New York 11
Florida 11
Arizona 11
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Florbetapir F-18

Clinical Trial Phase

Clinical Trial Phase for Florbetapir F-18
Clinical Trial Phase Trials
Phase 4 9
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Florbetapir F-18
Clinical Trial Phase Trials
Completed 31
Recruiting 6
Unknown status 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Florbetapir F-18

Sponsor Name

Sponsor Name for Florbetapir F-18
Sponsor Trials
Avid Radiopharmaceuticals 27
Eli Lilly and Company 3
Biogen 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Florbetapir F-18
Sponsor Trials
Industry 37
Other 22
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
Express Scripts
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.